Abstract

Glutamate is the major excitatory neurotransmitter of the central nervous system (CNS) and may induce cytotoxicity through persistent activation of glutamate receptors and oxidative stress. Its extracellular concentration is maintained at physiological concentrations by high affinity glutamate transporters of the solute carrier 1 family (SLC1). Glutamate is also present in islet of Langerhans where it is secreted by the α-cells and acts as a signaling molecule to modulate hormone secretion. Whether glutamate plays a role in islet cell viability is presently unknown. We demonstrate that chronic exposure to glutamate exerts a cytotoxic effect in clonal β-cell lines and human islet β-cells but not in α-cells. In human islets, glutamate-induced β-cell cytotoxicity was associated with increased oxidative stress and led to apoptosis and autophagy. We also provide evidence that the key regulator of extracellular islet glutamate concentration is the glial glutamate transporter 1 (GLT1). GLT1 localizes to the plasma membrane of β-cells, modulates hormone secretion, and prevents glutamate-induced cytotoxicity as shown by the fact that its down-regulation induced β-cell death, whereas GLT1 up-regulation promoted β-cell survival. In conclusion, the present study identifies GLT1 as a new player in glutamate homeostasis and signaling in the islet of Langerhans and demonstrates that β-cells critically depend on its activity to control extracellular glutamate levels and cellular integrity.

Highlights

  • Ing ␤-cells and concomitant insulin resistance [1,2,3]

  • ␤TC3 Cells Are Vulnerable to Glutamate-induced Cytotoxicity—We first determined whether ␤- and ␣-cell lines were vulnerable to extracellular glutamate. ␤TC3 and ␣TC1 were cultured in the presence of different glutamate concentrations, and cell viability was assayed by the MTT test

  • Naϩ-dependent Glutamate Transporter glutamate transporter 1 (GLT1) Is Selectively Expressed by ␤-Cells—We explored whether ␤-cells express a glutamate clearance system that controls the extracellular glutamate concentration

Read more

Summary

The abbreviations used are

T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; GLT1, glial glutamate transporter 1; SLC1, solute carrier 1; EAAT, excitatory amino acid transporter; xϪc, glutamate/cysteine exchanger; EAAC1, excitatory amino acid carrier 1; GLAST, glutamate-aspartate transporter; ASCT2, alanine-serine-cysteine transporter 2; SAT2, system A transporter 2; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; DHK, dihydrokainate; CEF, ceftriaxone; CNQX, 6-cyano-7-nitroquinoxaline-2,3-dione; 4-HNE, 4-hydroxy-2-nonenal; PDM, product of the differences from the mean intensity; HIP-A, 3-hydroxy4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]isoxazole-4-carboxylic acid; AMPA, ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid. GLT1/EAAT2 Prevents Glutamate-induced ␤-Cell Death (EAAT1–5) have been described [21], but GLT1/EAAT2 exhibits the highest level of expression in the CNS [22]. Mice deficient in GLT1 show increased susceptibility to acute cortical injuries [23], and inhibition of GLT1 activity increases the glutamate concentration to toxic levels [22]. We demonstrate that ␤-cells are selectively vulnerable to glutamate-induced toxicity and that GLT1 is present and functional in the islet where it influences glucagon release and promotes ␤-cell survival. Positive cells were counted by two independent observers using a 40ϫ objective from at least 40 randomly selected fields per coverslip. ␤TC3 cells were incubated for 5 days in 5 mM glutamate and lysed using a standard method. A standard curve was generated using 0 – 0.5 mM reduced GSH

EXPERIMENTAL PROCEDURES
RESULTS
Findings
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call